Current and Emerging Treatment Options for Patients With Relapsed Small-cell Lung Carcinoma: A Systematic Literature Review

Bernabé, R.; Chen, Yuanbin; Dowlati, Afshin; Eason, Paula

doi:10.1016/j.cllc.2023.01.012

Cited by 9 publications

(1 citation statement)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The National Comprehensive Cancer Network (NCCN) guideline (version 2.2023) ( 17 ) states that a rechallenge of the original regimen or a similar platinum-based regimen is recommended as a subsequent treatment option if the disease-free interval is longer than 6 months and that rechallenge of the original regimen or a similar platinum-based regimen may be considered if the disease-free interval is at least 3–6 months. Other recommended regimens in this setting include topotecan, lurbinectedin, cyclophosphamide/doxorubicin/vincristine (CAV), docetaxel, etoposide, gemcitabine, irinotecan, nivolumab, paclitaxel, pembrolizumab, temozolomide, and vinorelbine (category 2A) ( 22 ).…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of sintilimab in combination with chemotherapy for recurrent extensive-stage small cell lung cancer: a real-world retrospective study

Wang,

Liang,

et al. 2024

J Thorac Dis

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of sintilimab in combination with chemotherapy for recurrent extensive-stage small cell lung cancer: a real-world retrospective study

Wang,

Liang,

et al. 2024

J Thorac Dis

View full text Add to dashboard Cite

Continuing immune checkpoint inhibitors after progression: Real-world patterns of care and outcomes in second-line treatment for extensive-stage small-cell lung cancer

Zhang,

Bao,

et al. 2025

Lung Cancer

View full text Add to dashboard Cite

Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial

Han,

Guo,

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Treatment options for patients with relapsed extensive-stage small cell lung cancer (ES-SCLC) remain scarce. This study aims to evaluate the efficacy and safety of combining anlotinib and sintilimab plus chemotherapy as a second line or later therapy for ES-SCLC patients. This is a phase II clinical trial (ChiCTR2100049390) conducting at Shandong Cancer Hospital. Patients with ES-SCLC and received at least one prior systemic treatment were enrolled. The trial design involved a combination therapy (sintilimab, anlotinib, and nab-paclitaxel) administered over six 21-day cycles, followed by maintenance sintilimab therapy. The primary endpoint was objective response rate (ORR). Circulating tumor DNA sequencing was employed for exploratory analysis. From July 2021 to April 2023, 25 eligible patients were enrolled. The confirmed ORR was 60% (95% CI: 38.7–78.9%) and the DCR was 76% (95% CI: 54.9–90.6%). The mPFS was 6.0 months (95% CI: 5.4–9.7), and the 6-month PFS rate was 49.2%. The mOS was 13.4 months (95% CI: 11.8-NR), with a 12-month survival rate of 62.2%. Treatment-related adverse events (TRAEs) of any grade occurred in 80% of patients, with the most common being fatigue (40%) and nausea (32%). TRAEs of Grade 3 or higher were reported in 12% of patients. ctDNA analysis indicated that low on-treatment blood tumor mutation burden was associated with longer PFS and OS and a potential role of KMT2D mutation in treatment resistance. This combination therapy shows promising efficacy and a manageable safety profile as a second-line or later treatment for ES-SCLC, with genomic insights providing potential biomarkers for treatment response.

show abstract

Current and Emerging Treatment Options for Patients With Relapsed Small-cell Lung Carcinoma: A Systematic Literature Review

Cited by 9 publications

References 88 publications

Efficacy and safety of sintilimab in combination with chemotherapy for recurrent extensive-stage small cell lung cancer: a real-world retrospective study

Efficacy and safety of sintilimab in combination with chemotherapy for recurrent extensive-stage small cell lung cancer: a real-world retrospective study

Continuing immune checkpoint inhibitors after progression: Real-world patterns of care and outcomes in second-line treatment for extensive-stage small-cell lung cancer

Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial

Contact Info

Product

Resources

About